AZD9898

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

AZD9898 是一种口服活性白三烯-C4 合成酶（LTC4S，谷胱甘肽 S-转移酶 II）抑制剂，IC50 为 0.28 nM。 AZD9898 具有治疗哮喘的潜力。 AZD9898 减轻 GABA 结合和肝毒性信号。

AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 has the potential to treat asthma. AZD9898 mitigates the GABA binding and hepatic toxicity signal.(In Vivo):AZD9898 (10 and 100 mg/kg; oral) is well tolerated and shows no safety concerns.

——

AZD9898 with the single dose of 100 mg/kg is well tolerated and no safety concerns are raised. Animal Model:Rat 6M/group.Dosage:10 and 100 mg/kg (for Toxicology Study).Administration:Sing oral dose.Result:Showed no signs of testicular toxicity, and only adaptive changes in the liver due to cytochrome P450 induction which were not judged adverse, providing a 200 fold margin between the no adverse effect level and the predicted human exposure at the predicted therapeutic dose.

——

Others

Other Targets

Antifungal

——

——

2042347-69-1

457.83

C20H19ClF3N3O4

>98% (HPLC)

In Vitro:?DMSO : ≥ 250 mg/mL (546.05 mM)

COc1nc(cnc1C(=O)[C@H]1C[C@@H]1C(O)=O)N(CC(C)(C)F)c1cc(Cl)c(F)cc1F

——

(-20℃)

With Ice Pack

≥ 2 years